Active ingredient
Posaconazole
37 finished FDA listings contain Posaconazole as their only active ingredient.
FDA NDC Directory
- Ingredient names as written by FDA
- POSACONAZOLE
- Dosage forms
- Injection, Injection, Solution, Powder, For Suspension, Solution, Suspension, Tablet, Tablet, Coated, Tablet, Delayed Release
- Routes
- Intravenous, Oral
- Manufacturers / labelers
- 29
- Strengths listed
- 100 mg/1 · 18 mg/ml · 300 mg/1 · 40 mg/ml
- Brand names in FDA listings
- Noxafil, Posaconazole
RxNorm (National Library of Medicine)
Ingredient concept RxCUI 282446
Drugs@FDA applications
Linked only where the FDA listing’s application number matches Drugs@FDA exactly. A listing in the NDC Directory does not by itself mean FDA approval.
| Application | Sponsor | Original approval | Listings |
|---|---|---|---|
| NDA 022003 | SCHERING | 2006-09-15 | 2 |
| NDA 205053 | MERCK SHARP DOHME | 2013-11-25 | 2 |
| NDA 205596 | MERCK SHARP DOHME | 2014-03-13 | 1 |
| ANDA 212411 | SINOTHERAPEUTICS INC | 2019-08-21 | 4 |
| ANDA 208773 | HIKMA | 2020-05-15 | 1 |
| ANDA 213454 | AET PHARMA | 2021-02-01 | 2 |
| NDA 214770 | MSD MERCK CO | 2021-05-31 | 1 |
| ANDA 214476 | BIOCON PHARMA | 2022-02-04 | 1 |
| ANDA 212500 | DR REDDYS | 2022-04-07 | 2 |
| ANDA 212226 | SPECGX LLC | 2022-05-10 | 2 |
| ANDA 208768 | PH HEALTH | 2022-05-25 | 1 |
| ANDA 214321 | HETERO LABS LTD III | 2022-12-08 | 2 |
| ANDA 216626 | AMNEAL | 2022-12-22 | 2 |
| ANDA 216488 | PHARMAZONE | 2023-08-28 | 5 |
| ANDA 211500 | MYLAN LABS LTD | 2023-12-26 | 1 |
| ANDA 209983 | FRESENIUS KABI USA | 2023-12-26 | 1 |
| ANDA 214842 | EUGIA PHARMA | 2023-12-26 | 1 |
| ANDA 217553 | GLAND | 2023-12-26 | 3 |
| ANDA 217119 | AUROBINDO PHARMA | 2024-07-18 | 1 |
| ANDA 219057 | ASPIRO | 2024-12-23 | 1 |
| ANDA 218434 | MSN | 2025-02-24 | 1 |
Official labeling on DailyMed
- POSACONAZOLE TABLET, DELAYED RELEASE [DR.REDDYS LABORATORIES INC] · version 16 · 2026-09-02
- POSACONAZOLE TABLET, DELAYED RELEASE [SPECGX LLC] · version 14 · 2026-08-17
- POSACONAZOLE TABLET, DELAYED RELEASE [AUROBINDO PHARMA LIMITED] · version 3 · 2026-08-13
- POSACONAZOLE SOLUTION [MYLAN INSTITUTIONAL LLC] · version 3 · 2026-07-31
- POSACONAZOLE SUSPENSION [HIKMA PHARMACEUTICALS USA INC.] · version 11 · 2026-07-10
- POSACONAZOLE TABLET, DELAYED RELEASE [MAJOR PHARMACEUTICALS] · version 8 · 2026-06-10
- POSACONAZOLE INJECTION, SOLUTION [GLAND PHARMA LIMITED] · version 9 · 2026-06-10
- POSACONAZOLE TABLET, DELAYED RELEASE [LUPIN PHARMACEUTICALS, INC.] · version 9 · 2026-05-26
- POSACONAZOLE INJECTION [PAR HEALTH USA, LLC] · version 20 · 2026-04-27
- POSACONAZOLE TABLET, DELAYED RELEASE [ATLANTIC BIOLOGICALS CORP.] · version 4 · 2026-04-24
- POSACONAZOLE TABLET, DELAYED RELEASE [AMNEAL PHARMACEUTICALS NY LLC] · version 9 · 2026-04-10
- NOXAFIL (POSACONAZOLE) SUSPENSION NOXAFIL (POSACONAZOLE) TABLET, COATED NOXAFIL (POSACONAZOLE) SOLUTION NOXAFIL (POSACONAZOLE) POWDER, FOR SUSPENSION [MERCK SHARP & DOHME LLC] · version 56 · 2026-03-06
Showing the 12 most recent of 33 labels.
Sources: FDA NDC Directory (2026-09-29), RxNorm, Drugs@FDA, DailyMed. Each source’s facts are shown separately as published.